



Final Appraisal Recommendation

Tipranavir (Aptivus[®]▼) oral solution

Limited submission by:
Boehringer Ingelheim Ltd

Advice No: 2110 – December 2010

Recommendation of AWMSG

Tipranavir (Aptivus[®]▼) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus[®]▼) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.

Tipranavir (Aptivus[®]▼) oral solution is not suitable for shared care within NHS Wales for the above indication.

Additional notes:

The potential for drug interaction should be taken into consideration when prescribing.

Differences in bioavailability should be noted when formulation changes are considered.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: